Compounds > pentaacetylgitoxin
Page last updated: 2024-11-12

pentaacetylgitoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pentaacetylgitoxin: structure; RN given refers to (3beta,5beta,16beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20055093
CHEMBL ID3989807
SCHEMBL ID1132083
MeSH IDM0065771

Synonyms (25)

Synonym
7242-04-8
gitoxin pentaacetate
penta-o-acetylgitoxin
pengitoxin [inn]
cordoval
pengitossina [dcit]
carnacid-cor
pengitoxinum [inn-latin]
pentaacetylgitoxin
pengitoxine [inn-french]
einecs 230-645-5
pengitoxina [inn-spanish]
15rpl803r9 ,
unii-15rpl803r9
pengitoxinum
pengitoxine
pengitoxina
pengitossina
gitoxin pentaacetate [mi]
pengitoxin [who-dd]
pengitoxin [mart.]
SCHEMBL1132083
CHEMBL3989807
Q27251737
[(2r,3r,4s,6r)-3-[(2s,4s,5r,6r)-4-acetyloxy-5-[(2s,4s,5r,6r)-4,5-diacetyloxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-acetyloxy-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Following an open two-compartment model a mean elimination half-life of 60."( On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.
Alken, RG; Becker, U; Haustein, KO; Lach, HJ; Rietbrock, N, 1983)		0.27

Bioavailability

ExcerptReferenceRelevance
" In six volunteers the bioavailability of 16AG from two PAG tablet formulations (1."( On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.
Haustein, KO, 1986)		0.27

Dosage Studied

ExcerptRelevanceReference
" On the 3rd day of the pengitoxin dosage schedule, a mean plasma level of 18."( Pharmacokinetics of pengitoxin and its therapeutic efficacy in congestive heart failure.
Haustein, KO; Wesser, M, 1988)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.88 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pentachlorophenol
PENTA: structure given in first source		1.9410aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes		human xenobiotic metabolite
lanatosides
Lanatosides: Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale, The Extra Pharmacopoeia, 30th ed, p670)		1.9710
digitoxin
Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.		2.8740cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
glycosides
[no description available]		1.9710
lanatoside c
lanatoside C: RN given refers to (3beta,5beta,12beta)-isomer		1.9710
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		3.3570cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
acetyldigitoxin
Acetyldigitoxins: Cardioactive derivatives of lanatoside A or of DIGITOXIN. They are used for fast digitalization in congestive heart failure.. 3'''-O-acetyldigitoxin : A cardenolide glycoside compound consisting of digitoxin having an acetyl substituent at the 3-position on the D-ribo-hexopyranosyl residue at the non-reducing end.		1.9410cardenolide glycosideanti-arrhythmia drug;
cardiotonic drug;
enzyme inhibitor
beta-acetyldigoxin
Acetyldigoxins: Alpha- or beta-acetyl derivatives of DIGOXIN or lanatoside C from Digitalis lanata. They are better absorbed and longer acting than digoxin and are used in congestive heart failure.		3.66100cardenolide glycoside
16-acetylgitoxin
16-acetylgitoxin: main cardioactive metabolite of penta-acetylgitoxin. 16-O-acetylgitoxin : A cardenolide glycoside that is the 16-acetate of gitoxin.		2.8840acetate ester;
cardenolide glycoside
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiac Diseases
[description not available]		02.3420
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		02.3420
Cardiac Failure
[description not available]		02.3720
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.3720
Liver Dysfunction
[description not available]		01.9710
Liver Diseases
Pathological processes of the LIVER.		01.9710